Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Singer

Showing results (561-570 of 649) with videos related to

Pageof 65
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
Breast Cancer Research and Treatment|February 18, 2026
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Breast Cancer Research and Treatment|March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Cancer Research|July 30, 2011
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting GenesTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Journal of Medical Genetics|June 4, 2024
Validation of the BOADICEA model in a prospective cohort of <i>BRCA1/2</i> pathogenic variant carriersXin Yang, Thea M Mooij, Goska Leslie, et al.
Human Molecular Genetics|April 27, 2010
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriersXianshu Wang, V Shane Pankratz, Zachary Fredericksen, et al.
JAMA Surgery|July 19, 2023
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast CancerWalter P Weber, Zoltan Matrai, Stefanie Hayoz, et al.
Pageof 65

Showing results (561-570 of 649) with videos related to

Sort By:
Pageof 65
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 7, 2021
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)Michael Gnant, Amylou C Dueck, Sophie Frantal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriersKelly-Anne Phillips, Roger L Milne, Matti A Rookus, et al.
NPJ Breast Cancer|September 23, 2020
Association of germline variation with the survival of women with <i>BRCA1/2</i> pathogenic variants and breast cancerTaru A Muranen, Sofia Khan, Rainer Fagerholm, et al.
Breast Cancer Research and Treatment|February 18, 2026
Correction: Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
ESMO Open|June 5, 2025
Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)M J Naughton, D M Zahrieh, M Gnant, et al.
Breast Cancer Research and Treatment|March 27, 2025
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancerEileen Shinn, David Zahrieh, Angela DeMichele, et al.
Cancer Research|July 30, 2011
Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting GenesTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.
Journal of Medical Genetics|June 4, 2024
Validation of the BOADICEA model in a prospective cohort of <i>BRCA1/2</i> pathogenic variant carriersXin Yang, Thea M Mooij, Goska Leslie, et al.
Human Molecular Genetics|April 27, 2010
Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriersXianshu Wang, V Shane Pankratz, Zachary Fredericksen, et al.
JAMA Surgery|July 19, 2023
Association of Axillary Dissection With Systemic Therapy in Patients With Clinically Node-Positive Breast CancerWalter P Weber, Zoltan Matrai, Stefanie Hayoz, et al.
Pageof 65